Tech decoded by AI
50 articles analyzed by AI / 352 total
A suspect involved in the April 2024 attack on OpenAI CEO Sam Altman's home has been charged with attempted murder, highlighting serious security incidents surrounding OpenAI leadership in multiple cities including San Francisco and Spring, Texas.
On April 14, 2026, OpenAI unveiled GPT-5.4-Cyber, an AI model specifically designed for defensive cybersecurity applications, aiming to enhance protection against growing hacking threats by providing specialized tools for vetted security professionals.
Novo Nordisk announced a collaboration with OpenAI on April 14, 2026, to accelerate drug discovery and transform pharmaceutical R&D through AI-driven healthcare innovation, signaling a strategic partnership between AI and pharmaceutical industries.
OpenAI's upcoming GPT-6 model, codenamed 'Spud', is anticipated to begin the 'Stargate era' of AI development, with heightened market expectations for its launch, marking a key milestone in OpenAI’s product roadmap.
On April 14, 2026, OpenAI acquired Hiro Finance, a startup specializing in AI-powered personal finance advisory solutions, reflecting OpenAI’s strategic expansion into the financial technology sector.
OpenAI launched GPT-5.4-Cyber, designed for vetted security professionals, emphasizing its commitment to specialized AI tools in cybersecurity, and reinforcing its role in AI for cyber defense.
OpenAI's valuation at $852 billion is under investor scrutiny as the company pivots towards enterprise AI solutions, raising questions about its financial strategy and long-term growth amidst evolving market conditions.
Greg Brockman, president of OpenAI, stated on April 14, 2026, that nearly one billion people now use OpenAI’s ChatGPT and Codex products weekly, underlining the company's vast reach and user engagement.
In December 2025, Disney announced a $1 billion investment in OpenAI along with licensing its characters for OpenAI’s Sora AI tool, signifying a major strategic partnership in entertainment and AI technology.
On April 14, 2026, Novo Nordisk and OpenAI officially announced their partnership to accelerate drug discovery by integrating AI technology, marking a significant step forward in AI-driven pharmaceutical research and development.